Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383156 | 0.88 | CNR1 (0.62) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4387900 | 0.84 | CNR1 (0.60) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10305393 | 0.80 | CNR1 (0.71) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10156473 | 0.79 | CNR1 (0.67) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4481857 | 0.79 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10305368 | 0.79 | CNR1 (0.78) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1707522 | 0.79 | CNR1 (0.66) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12191426 | 0.79 | CNR1 (0.51) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4476513 | 0.78 | CNR1 (0.63) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1707014 | 0.77 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891074-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1891074-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1891074-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006138682-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CYP2C9 375/4885CYP2C19 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.